grant
Effects of tobacco smoking on prognosis and immune function in multiple sclerosis
Organization OKLAHOMA MEDICAL RESEARCH FOUNDATIONLocation OKLAHOMA CITY, UNITED STATESPosted 1 Jun 2025Deadline 28 Feb 2030
NIHUS FederalResearch GrantFY2026AddressAdverse effectsAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAssayAutoimmune DiseasesAutoimmune StatusAutoimmunityAutomobile DrivingB blood cellsB cellB cell depletion therapyB cell directed therapyB cell targeted therapyB cell therapiesB cell therapyB cellsB-Cell ActivationB-CellsB-LymphocytesB-cellBenignBioassayBiological AssayBloodBlood Reticuloendothelial SystemBlood SerumCNS Nervous SystemCTLA-8CTLA-8 GeneCTLA8CTLA8 GeneCell BodyCell CommunicationCell Communication and SignalingCell Culture TechniquesCell InteractionCell SignalingCell-to-Cell InteractionCellsCellular Immune FunctionCellular StressCellular Stress ResponseCentral Nervous SystemChronicClinicalClinical DataClinical ManagementCopaxoneCytotoxic T-Lymphocyte-Associated Antigen 8Cytotoxic T-Lymphocyte-Associated Antigen 8 GeneCytotoxic T-Lymphocyte-Associated Serine Esterase 8Cytotoxic T-Lymphocyte-Associated Serine Esterase 8 GeneDataDemyelinationsDevelopmentDiagnosisDiseaseDisease ProgressionDisorderDisseminated SclerosisEndogenous Interferon BetaEnvironmental FactorEnvironmental Risk FactorExhibitsFibroblast InterferonFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFumaratesHealthHelper CellsHelper T-CellsHelper T-LymphocytesHelper-Inducer T-CellsHelper-Inducer T-LymphocyteHeterogeneityIFN-βIFNbIL-17IL-17 GeneIL-17AIL-17A GeneIL17IL17 ProteinIL17 geneIL17AIL17A GeneImmuneImmunesImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologicsIndividualInducer CellsInducer T-LymphocytesInflammationInflammation MediatorsInflammatoryInterferon-βInterleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8) GeneInterleukin 17 PrecursorInterleukin 17 Precursor GeneInterleukin-17Intracellular Communication and SignalingKnowledgeLinkMS patientMS treatmentMeasuresMethodsMolecularMonitorMultiple SclerosisNatural Interferon BetaNatural human interferon betaNerve CellsNerve UnitNeural CellNeuraxisNeurocyteNeuronsPBMCPathway interactionsPatientsPatternPeripheral Blood Mononuclear CellPhenotypePlayPopulationPrognosisProgressive DiseaseProteinsProteomicsRelapseRelapsing-Remitting Multiple SclerosisResearchSerumSignal TransductionSignal Transduction SystemsSignalingSmokerSmokingSmoking StatusTestingTherapeuticTobacco smokeTobacco smokingTobacco smoking behaviorVariantVariationactivated B cellsautoimmune conditionautoimmune disorderautoimmunity diseasebiological signal transductioncell culturecell culturescell stresscigarette smokeclinical effectclinical heterogeneityclinical prognosiscohortcopolymer 1copolymer Icytokinedemyelinatedevelopmentaldisabilitydisableddisease prognosisdisease prognosticationdrivingdrug efficacyenvironmental riskexosomeextracellular vesiclesflow cytophotometryglatiramer acetateimmune functionimprovedin vitro Assayinflammatory mediatorinsightinsular sclerosismultiple sclerosis patientmultiple sclerosis therapymultiple sclerosis treatmentneuronalnew markernon-smokernon-smokingnonsmokernonsmokingnovel biomarkernovel markerpathwaypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespatients with MSpatients with multiple sclerosispeople with Multiple sclerosispotential biological markerpotential biomarkerresponse to therapyresponse to treatmenttherapeutic responsetherapy responsetranscriptomicstreatment responsetreatment responsiveness
Description preview
PROJECT SUMMARY
Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by central nervous system (CNS)
inflammation and neuronal demyelination. Despite therapeutic advancements, the clinical heterogeneity among
MS patients presents challenges in accurately predicting and monitoring disease progression. While previous
studies have…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click